Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

RDN for CKD and Uncontrolled Hypertension Trial

16 de noviembre de 2026 actualizado por: Beijing Anzhen Hospital

Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

248

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Luyun Fan
  • Número de teléfono: +86-13522601484
  • Correo electrónico: katevan@163.com

Copia de seguridad de contactos de estudio

  • Nombre: Jingjing Zhou
  • Número de teléfono: +86-18742568090
  • Correo electrónico: zhoujjrf0901@163.com

Ubicaciones de estudio

      • Beijing, Porcelana, 101118
        • Reclutamiento
        • Beijing Anzhen Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female, aged 18 to 65 years, inclusive, at the time of consent;
  2. Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
  3. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
  4. The presence or absence of accessory renal arteries is acceptable;
  5. The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.

Exclusion Criteria:

  1. Pregnant or breastfeeding, or planning pregnancy during the study.
  2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
  3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
  4. Prior renal artery intervention or prior renal denervation.
  5. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
  6. Allergic to contrast agents.
  7. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
  8. Orthostatic hypotension.
  9. Type 1 diabetes mellitus.
  10. Primary pulmonary arterial hypertension.
  11. History of bleeding diathesis and haematological disorders or coagulopathy
  12. History of thromboembolic event within 6 months.
  13. History of stroke or transient ischemic attack (TIA) within 6 months.
  14. Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
  15. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
  16. NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
  17. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
  18. Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
  19. Severe hepatic dysfunction.
  20. Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
  21. Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
  22. Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
  23. Acute or severe systemic infection.
  24. Other conditions deemed unsuitable for participation by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Renal Denervation (RDN)

Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system

Otros nombres:
  • Denervación Renal
Comparador falso: Parallel control with sham operation

Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

Otros nombres:
  • Angiografía renal

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
Periodo de tiempo: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline

Baseline to Month 6 post-procedure

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
Periodo de tiempo: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Month 6 post-procedure
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
Periodo de tiempo: Baseline to Months 1, 3, 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Baseline to Months 1, 3, 6 and 12 post-procedure
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
Periodo de tiempo: Baseline to Months 1, 3, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Months 1, 3, and 12 post-procedure
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
Periodo de tiempo: Baseline to Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring

Baseline to Months 1, 3, 6, and 12 post-procedure
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
Periodo de tiempo: Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Months 1, 3, 6, and 12 post-procedure
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
Periodo de tiempo: Months 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Months 6 and 12 post-procedure
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
Periodo de tiempo: Months 6 and 12 post-procedure

Proportion of participants with a reduction ≥5 mmHg from baseline in office BP

Months 6 and 12 post-procedure
Change from Baseline in Antihypertensive Medication Use
Periodo de tiempo: Months 1, 3, 6 and 12 post-procedure

Change in the number of concurrently prescribed antihypertensive agents

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in serum creatinine levels
Periodo de tiempo: Months 1, 3, 6 and 12 post-procedure

Change in postoperative serum creatinine levels relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in glomerular filtration rate
Periodo de tiempo: Months 1, 3, 6 and 12 post-procedure

Changes in glomerular filtration rate relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in the urine microalbumin-to-creatinine ratio
Periodo de tiempo: Months 1, 3, 6 and 12 post-procedure

Changes in the urine microalbumin-to-creatinine ratio relative to baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in Heart Rate (by ECG)
Periodo de tiempo: Months 1, 3, 6 and 12 post-procedure

Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
Periodo de tiempo: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure
Change from Baseline in left ventricular mass index
Periodo de tiempo: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de diciembre de 2025

Finalización primaria (Estimado)

31 de octubre de 2027

Finalización del estudio (Estimado)

30 de abril de 2028

Fechas de registro del estudio

Enviado por primera vez

26 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • BRWEP2024W012060105

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .